Search Results
Your search for Stephen M. Ansell, MD, PhD,Stephen M. Ansell, MD, PhD matches 21 pages
Showing 1 - 21
Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD: New Findings on How the IRF4 Gene Shapes Tumor Immunity in Follicular Lymphoma
Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD, both of the Mayo Clinic, discuss the 20% of patients with follicular lymphoma (FL) who relapse early and experience a poor prognosis. The researchers found that FLs with high levels of IRF4 expression are associated with a suppressive...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...
Addition of Brentuximab Vedotin to Chemotherapy in Patients With Stage III or IV Hodgkin Lymphoma: Overall Survival Analysis From ECHELON-1
As reported in The New England Journal of Medicine by Stephen M. Ansell, MD, PhD, and colleagues, an analysis at 6 years of follow-up in the phase III ECHELON-1 trial has shown significantly improved overall survival with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ...
Stephen M. Ansell, PhD, MD, on Hodgkin Lymphoma: An Updated Analysis on First-Line Brentuximab Vedotin Plus Chemotherapy
Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin,...
Bruce D. Cheson, MD, and Stephen M. Ansell, MD, PhD, on Non-Hodgkin and Follicular Lymphomas: Integrating Non–CAR T-Based Treatments
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, and Bruce D. Cheson, MD, of the Lymphoma Research Foundation, engage in a lively debate about CAR T-cell therapy, how it fits in with immunotherapy and nonchemotherapy approaches, and how to decide which treatment is right for which patient,...
Expert Point of View: Stephen M. Ansell, MD, PhD
Stephen M. Ansell, MD, PhD, Professor of Medicine in the Department of Hematology at the Mayo Clinic, Minnesota, underscored the importance of the HD17 trial results. “These data show, in a randomized fashion, that a PET-directed approach when using more intensive chemotherapy allows for the...
Nivolumab in Relapsed or Refractory DLBCL Ineligible for or After Failure of Autologous Transplantation
In a phase II trial reported in the Journal of Clinical Oncology, Ansell et al found that nivolumab was associated with low response rates among patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were ineligible for or experienced failure of autologous hematopoietic cell ...
For Hodgkin Lymphoma, PD-1 Blockade Is Not the Final Answer
Although programmed cell death protein 1 (PD-1) blockade is highly effective in Hodgkin lymphoma, not all patients respond, and not all responses are durable. Stephen M. Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group and Professor of Medicine at the Mayo Clinic, Rochester, described...
Stephen M. Ansell, MD, PhD, on Hodgkin Lymphoma: Beyond Checkpoint Inhibitors
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the efficacy of PD-1 blockade in Hodgkin lymphoma, new findings related to PD-1 therapy, current combination approaches, and future treatments.
Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.
Encouraging Results With Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
AN EFFECTIVE antitumor immune response relies on cytotoxic T cells that are activated and able to target the malignant clone. As T cells become activated, they upregulate suppressive receptors including programmed cell death protein 1 (PD-1). Upregulation of inhibitory signals is important to...
Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).
Nivolumab in Recurrent Classical Hodgkin Lymphoma: Refreshingly Supportive Data
It is commonly said that if something is too good to be true, it usually is. It is therefore quite refreshing when really good results are replicated in a subsequent study. As reported in The Lancet Oncology by Younes et al1 and reviewed in this issue of The ASCO Post, a phase II trial of...
Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
SIDEBAR: Addition of Novel Agents May Improve Outcomes With ABVD
In North America, the standard front-line treatment for advanced Hodgkin lymphoma is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), but this regimen is not effective in all patient subsets. To improve upon the regimen’s efficacy, researchers are evaluating new combinations, said Stephen...
Brentuximab Vedotin Improves Response Rates to ABVD in Hodgkin Lymphoma
For the front-line treatment of advanced Hodgkin lymphoma, ABVD is a standard treatment, but not all patients have good outcomes with this regimen. The addition of brentuximab vedotin (Adcetris), or its substitution for bleomycin, produces high complete response rates but with a moderate increase...
PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the programmed cell death protein 1 (PD-1) pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of the PD-1...
Brentuximab Vedotin After Autologous Stem Cell Transplantation in High-Risk Hodgkin Lymphoma: Implications of the AETHERA Trial
Hodgkin lymphoma is generally thought to be a malignancy with a favorable prognosis. Overall, approximately 80% of patients will have durable, long-term remissions with initial chemotherapy. Some patients, however, demonstrate evidence of disease progression, and these patients usually receive...
PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the PD-1 pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of PD-L1 and PD-L2 and promoting...
